Ankylosing Spondylitis References

Last updated: 29 October 2024
  1. Braun J, van der Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011 Jun;70(6):896-904. doi: 10.1136/ard.2011.151027. PMID: 21540199
  2. Braun J, Sieper J. Early diagnosis of spondyloarthritis. Nature Clin Prac Rheum. 2006 Oct;2(10):536-545. doi:10.1038/ncprheum0296. PMID: 17016479
  3. Akgul O, Ozgocmen S. Classification criteria for spondyloarthropathies. World J Orthop. 2011 Dec;2(12):107-115. http://www.wjgnet.com/2218-5836/pdf/v2/i12/107.pdf. Accessed 20 Sep 2013. PMID: 22474629
  4. Kain T, Zochling J, Taylor A, et al. Evidence-based recommendations for the diagnosis of ankylosing spondylitis: results from the Australian 3E initiative in rheumatology. Med J Aust. 2008 Feb;188(4):235-237. https://www.mja.com.au/system/files/issues/188_04_180208/kai10788_fm.pdf. PMID: 18279132
  5. Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009 Jun;68(Suppl 2):ii1-ii44. doi: 10.1136/ard.2008.104018. PMID: 19433414
  6. Harper BE, Reveille JD. Spondyloarthritis: clinical suspicion, diagnosis, and sports. Curr Sports Med Rep. 2009 Feb;8(1):29-34. doi: 10.1249/JSR.0b013e3181967ac6. PMID: 19142077
  7. Mansour M, Cheema GS, Naguwa SM, et al. Ankylosing spondylitis: a contemporary perspective on diagnosis and treatment. Semin Arthritis Rheum. 2007 Feb;36(4):210-223. http://www.ncbi.nlm.nih.gov/pubmed/?term=Ankylosing+spondylitis%3A+a+contemporary+perspective+on+diagnoss+and+treatment. PMID: 17011612
  8. National Institute for Health and Care Excellence (NICE). NICE recommends golimumab for ankylosing spondylitis. NICE. http://www.nice.org.uk/newsroom/pressreleases/GolimumabForAnkylosingSpondylitisFinalGuidance.jsp. Aug 2011.
  9. National Institute for Health and Care Excellence (NICE). NICE guidance on biologic drugs for the treatment of ankylosing spondylitis. NICE. http://www.nice.org.uk/newsroom/news/NICERecommendsDrugForTheTreatmentOfAnkylosingSpondylitis.jsp. Aug 2011.
  10. Keith MP. Overview of drug therapy for spondyloarthritis. Rheumatol Curr Res. 2013;3:119. http://omicsonline.org/overview-of-drug-therapy-for-spondyloarthritis-2161-1149.1000119.pdf.
  11. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan;73(1):6-16. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888616/pdf/annrheumdis-2013-203419.pdf. Accessed 27 May 2016. PMID: 23749611
  12. Mandl P, Navarro-Compán V, Terslev L, et al; European League Against Rheumatism (EULAR). EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis. 2015 Jul;74(7):1327-1339. http://ard.bmj.com/content/early/2015/04/02/annrheumdis-2014-206971.full.pdf+html. Accessed 27 May 2016. PMID: 25837448
  13. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016 Feb;68(2):282-298. doi: 10.1002/art.39298. Accessed 27 May 2016. PMID: 26401991
  14. Wendling D, Lukas C, Paccou J, et al; French Society for Rheumatology (SFR). Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine. 2014 Jan;81(1):6-14. doi: 10.1016/j.jbspin.2013.12.002. Accessed 27 May 2016. PMID: 24412120
  15. Forster D, Warburton L, O'Flynn N. Diagnosis and management of spondyloarthritis in the over-16s: NICE guideline. Br J Gen Pract. 2018 Jul;68(672):346-347. doi: 10.3399/bjgp18X697865. PMID: 29954812
  16. Mease P, Deodhar A. Differentiating nonradiographic axial spondyloarthritis from its mimics: A narrative review. BMC Musculoskelet Disord. 2022 Mar;23(1):240. doi: 10.1186/s12891-022-05073-7. PMID: 35279103
  17. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Ankylosing Spondylitis. NIH. https://www.niams.nih.gov/. May 2023.
  18. Navarro-Compán V, Boel A, Boonen A. The ASAS core measurement set for axial spondyloarthritis. Annals of Rheumatic Diseases. 2022;81:96-96. doi: 10.1136/annrheumdis-2022-eular.1798.
  19. Poddubnyy D. Classification vs diagnostic criteria: The challenge of diagnosing axial spondyloarthritis. Rheumatology. 2020 Oct;59(4):iv6-iv17. https://doi.org/10.1093/rheumatology/keaa250.
  20. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296.
  21. Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults. UpToDate. https://www.uptodate.com/. Jul 2023.
  22. Watson S. JAK inhibitors for ankylosing spondylitis. WebMD. https://www.webmd.com/.
  23. Yu D, Tubergen A. Diagnosis and differential diagnosis of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults. UpToDate. https://www.uptodate.com/. Jul 2023.
  24. van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults. UpToDate. https://www.uptodate.com/. 22 Jan 2024.
  25. Bautisa-Molano W, Fernández-Ávila DG, Brance ML, et al. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis. Nat Rev Rheumatol. 2023 Nov;19(11):724-737. doi: 10.1038/s41584-023-01034-z. PMID: 37803079
  26. U.S. Food & Drug Administration. Abrilada highlights of prescribing information. US FDA. https://www.fda.gov/. Nov 2019.
  27. Van der Heijde D, Baraliakos X, Sieper J, et al. POS0306 Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: a double-blind, randomized, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases. 2022;81:402-403. https://ard.bmj.com.
  28. Klavdianou K, Tsiami S, Baraliakos X. New developments in ankylosing spondylitis-status in 2021. Rheumatology (Oxford). 2021 Dec 24;60(Suppl 6):vi29-vi37. doi: 10.1093/rheumatology/keab523. PMID: 34951921
  29. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285-1299. doi: 10.1002/acr.24025. Accessed 14 Jun 2021. PMID: 31436026
  30. Tam LS, Wei JC, Aggarwal A, et al. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019 Mar;22(3):340-356. doi: 10.1111/1756-185X.13510. PMID: 30816645
  31. National Institute for Health and Care Excellence (NICE). Spondyloarthritis. NICE. http://www.nice.org.uk/. 28 Jun 2018. Accessed 14 Jun 2021.
  32. Inman RD. The spondyloarthropathies. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020. http://www.clinicalkey.com. Accessed 11 Jun 2021:1718-1725e3.
  33. ClinicalKey. Clinical overview: ankylosing spondylitis. ClinicalKey. http://www.clinicalkey.com. 30 October 2020.
  34. Yu DT, van Tubergen A. Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults. UpToDate. https://www.uptodate.com. 09 Jan 2020. Accessed 22 Nov 2018.
  35. Yu DT. Assessment and treatment of ankylosing spondylitis in adults. UpToDate. https://www.uptodate.com. May 2018. Accessed 22 Nov 2018.
  36. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-991. doi: 10.1136/annrheumdis-2016-210770. Accessed 14 Jun 2021. PMID: 28087505
  37. National Institute for Health and Clinical Excellence (NICE). Review of TA143; Adalimumab, etanercept and infliximab for ankylosing spondylitis. NICE. https://www.nice.org.uk/guidance/ta143/resources/guidance-adalimumab-etanercept-and-infliximab-for-ankylosing-spondylitis-pdf. May 2008.
  38. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006 Mar;65(3):316-320. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1798064/pdf/316.pdf. PMID: 16096329